GreyRigge

Executive Summary

GreyRigge Associates (GRA) is a London-based global biotech consultancy founded in 2010, specializing in biologics and advanced therapy medicinal products (ATMPs). The firm provides end-to-end services including CMC, regulatory affairs, quality assurance, and strategic planning, supporting clients from early-stage development through commercial launch. With deep expertise in complex therapeutic modalities, GRA has built a strong reputation in the biotech ecosystem, particularly as cell and gene therapies gain traction. The company operates as a private entity and is currently in Phase 3 stage, likely referring to its client projects rather than internal drug development. While consultancy revenues are recurring, growth depends on expanding client base and service depth. GRA is well-positioned to benefit from increasing regulatory complexity and the need for specialized ATMP development support.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Major Pharma for ATMP Development40% success
• Q4 2026Expansion of Service Offerings into Gene Editing and Companion Diagnostics50% success
• Q3 2026Announcement of Key Hire or Advisory Board Addition with Regulatory Expertise60% success